Nephron Research downgraded Qiagen (QGEN) to Hold from Buy with a $59 price target
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN:
- Qiagen: M&A Optionality Priced In Warrants Neutral Hold Amid Strategic Uncertainty
- Qiagen considering possible sale amid fresh takeover interest, Bloomberg says
- Qiagen trading resumes
- Qiagen resumes, up 10% after Bloomberg report of weighing strategic options
- Qiagen trading halted, volatility trading pause